What the study explored
Published in JAMA Psychiatry on October 21, 2026, this nonrandomized clinical trial followed 12 people living with mild-to-moderate Parkinson disease and mood dysfunction. Participants received two supported psilocybin sessions—10 mg followed approximately two weeks later by 25 mg.
The research team examined something especially significant: whether psilocybin therapy was accompanied by measurable changes in biological markers connected with systemic inflammation and mitochondrial stress. Plasma samples were available from nine participants.
What changed after psilocybin therapy
A composite of five proinflammatory markers—interleukin-6, interleukin-8, tumor necrosis factor alpha, interferon gamma and C-reactive protein—was lower one day after each psilocybin session. The reduction remained measurable 30 days after the second session.
Several individual markers also shifted. IL-6, IL-8 and C-reactive protein were lower after the first dose, while the anti-inflammatory cytokine IL-10 rose temporarily. GDF-15, a marker associated with mitochondrial stress, was lower the day after each session, although that change was not maintained at 30 days.
Why this research matters
Psilocybin research is often discussed primarily through changes in mood, perception and emotional experience. This study brings another layer into view: the possibility that psilocybin therapy may also influence inflammatory signaling and cellular stress in the human body.
That is particularly compelling in Parkinson disease, where neuroinflammation and mitochondrial dysfunction are active areas of scientific investigation. The study does not reduce healing to a single pathway. Instead, it points toward a more integrated research picture in which psychological experience, immune signaling and cellular energy systems may be studied together.
Avenues this opens for healing research
The findings invite larger controlled studies to explore how long these biological shifts last, whether they relate to changes in mood or neurological function, and which molecular pathways may be involved. They also strengthen a broader question now moving through psychedelic science: could the effects of psilocybin extend beyond the acute experience into measurable changes across interconnected systems of the body?
For Healing Rituals readers, the relevance is the expanding horizon of the research itself. Psilocybin is being investigated not only as a catalyst for subjective experience, but as a possible participant in biological processes related to inflammation, resilience and restoration.
Evidence status: Preliminary—use caution. This was an open-label study without a control group, and the biomarker analysis included nine participants. It offers a promising human signal and a clear direction for larger controlled research; it does not yet establish causation or clinical efficacy.
Source & further reading
- Psilocybin and Inflammatory and Mitochondrial Stress Markers in Parkinson Disease: A Nonrandomized Clinical TrialJAMA Psychiatry, published October 21, 2026.
Continue exploring
Read more about emerging psychedelic science, preparation and the wider arc of a supported healing journey.
Explore plant-assisted journeys